Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

A daily pill from drugmaker Eli Lilly has shown similar effectiveness ... The once-daily pill, called orforglipron, helped patients with Type 2 diabetes during late-stage trials and has shown ...

Eli Lilly said its experimental pill met its goals in a pivotal study, helping diabetes patients lower blood sugar—and even reduce weight, bringing an oral version of the booming class of drugs ...

Injectables for type 2 diabetes and weight loss could soon be a thing of the past. Eli Lilly announced Thursday the successful completion of a phase 3 trial of Orforglipron – the first small ...

Eli Lilly's shares were rallying ahead of the opening bell after the drug company's first GLP-1 pill for diabetes and weight loss took a step closer to hitting the market. In premarket trading ...

Eli Lilly experienced a 16% price increase last ... trial for Orforglipron highlight potential new treatments for type 2 diabetes. These innovative steps likely bolstered investor confidence ...

Eli Lilly announced the results of a clinical trial for its new pill, which the company said causes nearly 8% weight loss at certain dosages.

Eli Lilly said its phase 3 trial of GLP-1 ... “In the coming decades, 700 million people around the world will have Type 2 diabetes, and over a billion will have obesity,” Dr. Daniel Skovronsky, Lilly ...

Some of the potential iterations of delivery methods Eli Lilly considered for orforglipron ... But this one, for Lilly’s first diabetes and weight-loss pill based on the GLP-1 hormone, was ...